Login / Signup

Discovery of New Highly Potent Histamine H 3 Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase Inhibitors.

Rim MalekKinga SałatPerle TotosonTadeusz KarczBernard RefouveletAnna Skrzypczak-WierciochMaciej MajAlexey SimakovHelene MartinAgata SiwekNatalia SzałajJustyna GodyńDawid PanekAnna WięckowskaKrzysztof JozwiakCeline DemougeotKatarzyna Kieć-KononowiczFakher ChabchoubIsabel IriepaJosé Marco-ContellesLhassane Ismaili
Published in: ACS chemical neuroscience (2024)
At present, one of the most promising strategies to tackle the complex challenges posed by Alzheimer's disease (AD) involves the development of novel multitarget-directed ligands (MTDLs). To this end, we designed and synthesized nine new MTDLs using a straightforward and cost-efficient one-pot Biginelli three-component reaction. Among these newly developed compounds, one particular small molecule, named 3e has emerged as a promising MTDL. This compound effectively targets critical biological factors associated with AD, including the simultaneous inhibition of cholinesterases (ChEs), selective antagonism of H 3 receptors, and blocking voltage-gated calcium channels. Additionally, compound 3e exhibited remarkable neuroprotective activity against H 2 O 2 and Aβ 1-40 , and effectively restored cognitive function in AD mice treated with scopolamine in the novel object recognition task, confirming that this compound could provide a novel and innovative therapeutic approach for the effective treatment of AD.
Keyphrases
  • small molecule
  • working memory
  • metabolic syndrome
  • mild cognitive impairment